Antidepressants and pregnancy: What parents-to-be should know about ADHD, autism risks

Antidepressants and Pregnancy: What Parents-to-Be Should Know About ADHD, Autism Risks

Antidepressants and pregnancy – Recent years have seen increasing worries regarding the potential effects of antidepressants on developing fetuses, particularly regarding neurodevelopmental conditions like ADHD and autism. A new study has provided the most comprehensive analysis to date, examining the relationship between antidepressant use by both parents before and during pregnancy, and the likelihood of children developing these disorders. The findings, published in The Lancet Psychiatry, suggest that while initial associations were observed, most of these links diminish when other contributing factors are taken into account.

Study Methodology and Key Findings

The research team conducted a meta-analysis of 37 prior studies, encompassing over 600,000 pregnant women who used antidepressants and nearly 25 million pregnancies without such medication. By synthesizing this extensive data, the authors aimed to clarify the role of antidepressants in neurodevelopmental outcomes. Their results revealed that antidepressant exposure during either the pre-conception or prenatal period was largely not connected to ADHD or autism, once factors like genetics and family history were adjusted for.

Maternal use of antidepressants during pregnancy was initially associated with a 35% increased risk of ADHD and a 69% higher chance of autism, excluding cases with intellectual disabilities. Similarly, paternal antidepressant use showed a 46% rise in ADHD risk and a 28% elevation in autism likelihood. However, after accounting for confounders—such as hereditary predispositions and the reasons for medication use—these associations were significantly reduced. For autism, the risk dropped to around 15%, indicating that many of the earlier findings might have been influenced by external variables.

“This pattern strongly suggests that the higher rates of ADHD and autism seen in previously exposed groups are largely driven by the underlying vulnerability of these mothers and families,” said Dr. Wing Chung Chang, co-senior author of the study and clinical professor of psychiatry at the University of Hong Kong, via email.

Dr. Chang emphasized that antidepressants are a critical treatment for depressive disorders, which affect over 10% of pregnant women globally. The study also highlights how the conversation around antidepressant risks has been shaped by recent FDA discussions. In July 2025, an FDA expert panel considered updating warnings about SSRIs, the most commonly prescribed antidepressant class, to include potential risks like autism, miscarriage, and birth defects.

Chang noted that these discussions have intensified concerns, even as medical organizations pointed out that the warnings were “alarmingly unbalanced.” They argued that the panel overlooked the significant benefits of treating perinatal mood disorders, which can have severe consequences for both mothers and children. Past studies, while informative, were often limited by small sample sizes and inconsistent measurement of confounders, leading to conflicting conclusions.

Addressing the Overuse of Psychiatric Medications

The study was partly inspired by the growing debate around the overuse of psychiatric medications. Robert F. Kennedy Jr., a prominent figure in the discussion, launched an initiative to evaluate how antidepressants might influence child development. His efforts focus on scrutinizing the long-term impacts of these drugs, especially in light of the FDA’s evolving stance on their risks.

Chang explained that the research team sought to fill critical gaps in understanding. Previous work had not fully explored the effects of different antidepressant classes, specific drugs, dosage levels, or the combined role of both parents’ medication use. This comprehensive approach allowed the authors to provide a clearer picture of the risks and benefits associated with antidepressants during pregnancy.

“This concern has been amplified by the July 2025 FDA expert panel discussions about possibly strengthening warnings on SSRIs in pregnancy, highlighting potential risks such as autism, miscarriage, and birth defects,” Chang said.

Dr. Jonathan Alpert, a psychiatrist at Montefiore Medical Center, echoed the importance of informed decision-making. He stated that the impact of psychiatric medications on children is a natural concern for both parents and clinicians. “Pregnancy is inevitably a time of heightened worry about one’s health and the health of one’s unborn child,” Alpert added, noting that the study supports existing clinical guidelines.

The research underscores that current recommendations for continuing antidepressant treatment during pregnancy, when necessary, remain valid. “Our findings do not provide strong evidence that prenatal antidepressant exposure causes neurodevelopmental disorders,” Chang clarified. However, he stressed the need for thorough discussions between patients and healthcare providers to weigh the small potential risks of medication against the substantial risks of untreated maternal depression.

Implications for Parents and Clinicians

For expectant parents, the study offers reassurance that antidepressants are not inherently dangerous to fetal development, provided they are used under medical supervision. The findings challenge earlier perceptions that linked antidepressants to a higher incidence of ADHD and autism, suggesting that these conditions may have deeper roots in genetic and familial factors.

Chang and his team’s work also highlights the importance of personalized care. “Each case is unique, and the decision to use antidepressants during pregnancy should consider the individual’s mental health needs, family history, and other relevant factors,” he said. The study’s comprehensive analysis of 37 previous trials provides a robust foundation for clinicians to guide patients effectively.

Despite the study’s positive conclusions, some critics argue that more research is needed to confirm these results. They suggest that long-term follow-ups of children exposed to antidepressants in utero could reveal additional insights. Meanwhile, the authors advocate for a balanced view of the evidence, acknowledging both the risks of untreated depression and the benefits of medication.

Ultimately, the study reinforces the idea that antidepressants, while not without their complexities, are an essential tool for managing depression during pregnancy. By addressing the multifaceted nature of risk factors, the research helps to clarify the picture for parents and healthcare providers, ensuring that decisions are based on the most accurate and up-to-date information available.

Conclusion and Future Directions

As the debate continues, this study serves as a valuable resource for those navigating the decision to use antidepressants during pregnancy. It also sets the stage for further research into specific antidepressants, their dosages, and how they interact with other elements of maternal and paternal health. By offering a nuanced understanding of these factors, the study supports a more informed and balanced approach to managing mental health during pregnancy.